First-in-Class CD206 Agonist for Immunologically Cold Solid Organ Cancers

National Center For Advancing Translational Sciences

Investigators

Abstract

During this period, the TDB team advanced the preclinical development of NCGC72 through key activities. Pharmacokinetic (PK) and ADME (Absorption, Distribution, Metabolism, Excretion) studies to assess the compound's behavior in biological systems were completed. A non-GMP pilot batch of NCGC72 was synthesized and used for formulation development and ongoing dose range-finding (DRF) toxicology studies. The synthesis of GMP NCGC72 was completed to enable manufacturing of the drug product for subsequent GLP toxicology studies and clinical trials. During the collaboration, the therapeutic candidate was exclusively licensed by a clinical development partner. The TDB team transitioned into a collaborative agreement with the licensee to complete remaining IND enabling studies, which will form the basis for subsequent clinical trials.